JP2016510038A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016510038A5 JP2016510038A5 JP2015560381A JP2015560381A JP2016510038A5 JP 2016510038 A5 JP2016510038 A5 JP 2016510038A5 JP 2015560381 A JP2015560381 A JP 2015560381A JP 2015560381 A JP2015560381 A JP 2015560381A JP 2016510038 A5 JP2016510038 A5 JP 2016510038A5
- Authority
- JP
- Japan
- Prior art keywords
- membered
- independently
- alkyl
- optionally substituted
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 113
- 150000001875 compounds Chemical class 0.000 claims description 96
- 150000003839 salts Chemical class 0.000 claims description 94
- 125000000623 heterocyclic group Chemical group 0.000 claims description 86
- 229910052736 halogen Inorganic materials 0.000 claims description 63
- 150000002367 halogens Chemical class 0.000 claims description 63
- 239000003112 inhibitor Substances 0.000 claims description 61
- 125000004404 heteroalkyl group Chemical group 0.000 claims description 41
- 125000001188 haloalkyl group Chemical group 0.000 claims description 37
- 125000003342 alkenyl group Chemical group 0.000 claims description 35
- 125000000304 alkynyl group Chemical group 0.000 claims description 35
- 125000001072 heteroaryl group Chemical group 0.000 claims description 35
- 125000003118 aryl group Chemical group 0.000 claims description 32
- 239000008194 pharmaceutical composition Substances 0.000 claims description 30
- 108010078851 HIV Reverse Transcriptase Proteins 0.000 claims description 24
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 22
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 21
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 19
- 229910052757 nitrogen Inorganic materials 0.000 claims description 17
- 239000002777 nucleoside Substances 0.000 claims description 16
- 150000003833 nucleoside derivatives Chemical class 0.000 claims description 16
- 208000031886 HIV Infections Diseases 0.000 claims description 14
- 208000037357 HIV infectious disease Diseases 0.000 claims description 14
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims description 14
- 229940099797 HIV integrase inhibitor Drugs 0.000 claims description 12
- 239000003084 hiv integrase inhibitor Substances 0.000 claims description 12
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 12
- 125000003341 7 membered heterocyclic group Chemical group 0.000 claims description 11
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims description 10
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims description 10
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims description 10
- 125000006708 (C5-C14) heteroaryl group Chemical group 0.000 claims description 8
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 claims description 8
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 claims description 8
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 claims description 8
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 claims description 8
- 210000000234 capsid Anatomy 0.000 claims description 8
- 230000003197 catalytic effect Effects 0.000 claims description 8
- 239000002773 nucleotide Substances 0.000 claims description 8
- 125000003729 nucleotide group Chemical group 0.000 claims description 8
- 238000006116 polymerization reaction Methods 0.000 claims description 8
- 238000011282 treatment Methods 0.000 claims description 8
- 229940122440 HIV protease inhibitor Drugs 0.000 claims description 7
- 125000002619 bicyclic group Chemical group 0.000 claims description 7
- 125000002837 carbocyclic group Chemical group 0.000 claims description 7
- 239000004030 hiv protease inhibitor Substances 0.000 claims description 7
- 125000001620 monocyclic carbocycle group Chemical group 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 6
- 229940124784 gp41 inhibitor Drugs 0.000 claims description 6
- 125000004432 carbon atom Chemical group C* 0.000 claims description 5
- 229940124597 therapeutic agent Drugs 0.000 claims description 5
- 108010002459 HIV Integrase Proteins 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
- 125000000169 tricyclic heterocycle group Chemical group 0.000 claims description 3
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims 9
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 6
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 4
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 claims 2
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 claims 2
- 101800001690 Transmembrane protein gp41 Proteins 0.000 claims 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
- 125000006648 (C1-C8) haloalkyl group Chemical group 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 238000000034 method Methods 0.000 description 5
- 125000005059 halophenyl group Chemical group 0.000 description 4
- -1 methoxy, dimethylamino Chemical group 0.000 description 4
- 230000008901 benefit Effects 0.000 description 3
- 208000036142 Viral infection Diseases 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 108010010369 HIV Protease Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 125000002527 bicyclic carbocyclic group Chemical group 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- 125000005216 haloheteroaryl group Chemical group 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000013160 medical therapy Methods 0.000 description 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018114786A JP6893899B2 (ja) | 2013-03-01 | 2018-06-15 | Ｈｉｖの処置のためのアミド化合物 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361771655P | 2013-03-01 | 2013-03-01 | |
| US61/771,655 | 2013-03-01 | ||
| US201361857636P | 2013-07-23 | 2013-07-23 | |
| US61/857,636 | 2013-07-23 | ||
| PCT/US2014/019663 WO2014134566A2 (en) | 2013-03-01 | 2014-02-28 | Therapeutic compounds |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018114786A Division JP6893899B2 (ja) | 2013-03-01 | 2018-06-15 | Ｈｉｖの処置のためのアミド化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016510038A JP2016510038A (ja) | 2016-04-04 |
| JP2016510038A5 true JP2016510038A5 (OSRAM) | 2017-03-30 |
| JP6519486B2 JP6519486B2 (ja) | 2019-05-29 |
Family
ID=50382584
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015560381A Active JP6519486B2 (ja) | 2013-03-01 | 2014-02-28 | Ｈｉｖの処置のためのアミド化合物 |
| JP2018114786A Active JP6893899B2 (ja) | 2013-03-01 | 2018-06-15 | Ｈｉｖの処置のためのアミド化合物 |
| JP2019149366A Withdrawn JP2019214599A (ja) | 2013-03-01 | 2019-08-16 | Ｈｉｖの処置のためのアミド化合物 |
| JP2021177617A Withdrawn JP2022009742A (ja) | 2013-03-01 | 2021-10-29 | Ｈｉｖの処置のためのアミド化合物 |
| JP2023090106A Withdrawn JP2023101723A (ja) | 2013-03-01 | 2023-05-31 | Ｈｉｖの処置のためのアミド化合物 |
| JP2025039673A Pending JP2025085700A (ja) | 2013-03-01 | 2025-03-12 | Ｈｉｖの処置のためのアミド化合物 |
Family Applications After (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018114786A Active JP6893899B2 (ja) | 2013-03-01 | 2018-06-15 | Ｈｉｖの処置のためのアミド化合物 |
| JP2019149366A Withdrawn JP2019214599A (ja) | 2013-03-01 | 2019-08-16 | Ｈｉｖの処置のためのアミド化合物 |
| JP2021177617A Withdrawn JP2022009742A (ja) | 2013-03-01 | 2021-10-29 | Ｈｉｖの処置のためのアミド化合物 |
| JP2023090106A Withdrawn JP2023101723A (ja) | 2013-03-01 | 2023-05-31 | Ｈｉｖの処置のためのアミド化合物 |
| JP2025039673A Pending JP2025085700A (ja) | 2013-03-01 | 2025-03-12 | Ｈｉｖの処置のためのアミド化合物 |
Country Status (38)
Families Citing this family (84)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2553449T3 (es) | 2011-07-06 | 2015-12-09 | Gilead Sciences, Inc. | Compuestos para el tratamiento de VIH |
| EP2943487B1 (en) | 2013-01-09 | 2016-11-16 | Gilead Sciences, Inc. | 5-membered heteroaryls and their use as antiviral agents |
| TW201443037A (zh) * | 2013-01-09 | 2014-11-16 | Gilead Sciences Inc | 治療用化合物 |
| TWI694071B (zh) | 2013-03-01 | 2020-05-21 | 美商基利科學股份有限公司 | 治療反轉錄病毒科(Retroviridae)病毒感染之治療性化合物 |
| US9493429B2 (en) * | 2013-03-15 | 2016-11-15 | Genentech, Inc. | Substituted benzoxazoles and methods of use thereof |
| US10202353B2 (en) | 2014-02-28 | 2019-02-12 | Gilead Sciences, Inc. | Therapeutic compounds |
| EP3186239B1 (en) | 2014-08-29 | 2018-10-10 | Gilead Sciences, Inc. | Antiretroviral agents |
| WO2016040084A1 (en) | 2014-09-09 | 2016-03-17 | Bristol-Myers Squibb Company | Inhibitors of human immunodeficiency virus replication |
| US20160145344A1 (en) * | 2014-10-20 | 2016-05-26 | University Of Southern California | Murine and human innate lymphoid cells and lung inflammation |
| JP7381190B2 (ja) | 2014-12-26 | 2023-11-15 | エモリー・ユニバーシテイ | Ｎ４－ヒドロキシシチジン及び誘導体並びにそれに関連する抗ウイルス用途 |
| US10526323B2 (en) | 2015-01-30 | 2020-01-07 | Vanderbilt University | Indazole and azaindazole substituted compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| RU2017138972A (ru) | 2015-04-23 | 2019-05-23 | ВАЙВ ХЕЛТКЕР ЮКей (N5) ЛИМИТЕД | Ингибиторы репликации вируса иммунодефицита человека |
| JP2018513183A (ja) | 2015-04-23 | 2018-05-24 | ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド | ヒト免疫不全ウイルス複製の阻害剤 |
| US20170040479A1 (en) | 2015-08-07 | 2017-02-09 | Solaero Technologies Corp. | Reliable interconnection of solar cells |
| US20170081324A1 (en) * | 2015-09-18 | 2017-03-23 | F. Hoffmann-La Roche Ag | Triazolones derivatives and their use in the treatment, amelioration or prevention of a viral disease |
| JP2019519571A (ja) | 2016-06-30 | 2019-07-11 | ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド | ヒト免疫不全ウイルス複製のアザ置換阻害剤 |
| US20190135857A1 (en) | 2016-06-30 | 2019-05-09 | Viiv Healthcare Uk (No. 5) Limited | Triterpenoid inhibitors of human immunodeficiency virus replication |
| US10493070B2 (en) | 2016-06-30 | 2019-12-03 | Viiv Healthcare Uk (No. 5) Limited | Azadecalin derivatives as inhibitors of human immunodeficiency virus replication |
| EP3597646B1 (en) * | 2016-08-19 | 2023-06-21 | Gilead Sciences, Inc. | Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection |
| EA036921B1 (ru) * | 2017-02-10 | 2021-01-15 | Джилид Сайэнс, Инк. | Терапевтические соединения, которые можно применять для профилактического или терапевтического лечения инфекции вирусом вич |
| UY37710A (es) * | 2017-05-02 | 2018-11-30 | Viiv Healthcare Uk No 5 Ltd | Inhibidores de la replicación del virus de la inmunodeficiencia humana |
| AR112412A1 (es) * | 2017-08-17 | 2019-10-23 | Gilead Sciences Inc | Formas de sal de colina de un inhibidor de la cápside del vih |
| AR112413A1 (es) | 2017-08-17 | 2019-10-23 | Gilead Sciences Inc | Formas sólidas de un inhibidor de la cápside del vih |
| KR102626210B1 (ko) | 2017-12-07 | 2024-01-18 | 에모리 유니버시티 | N4-하이드록시사이티딘 및 유도체 및 이와 관련된 항-바이러스 용도 |
| WO2019161017A1 (en) | 2018-02-15 | 2019-08-22 | Gilead Sciences, Inc. | Pyridine derivatives and their use for treating hiv infection |
| US10696657B2 (en) * | 2018-02-16 | 2020-06-30 | Gilead Sciences, Inc. | Methods and intermediates for preparing therapeutic compounds |
| US11505543B2 (en) | 2018-04-11 | 2022-11-22 | VIIV Healthcare UK (No.5) Limited | 4-oxo-3,4-dihydroquinazoline compounds as inhibitors of human immunodeficiency virus replication |
| TWI842721B (zh) | 2018-07-16 | 2024-05-21 | 美商基利科學股份有限公司 | 用於治療hiv之蛋白殼抑制劑 |
| EP3833436A1 (en) * | 2018-08-09 | 2021-06-16 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
| EP3849982A1 (en) | 2018-09-14 | 2021-07-21 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
| JP7433303B2 (ja) | 2018-09-20 | 2024-02-19 | ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド | ヒト免疫不全ウイルス複製の阻害剤 |
| US20210395262A1 (en) | 2018-10-24 | 2021-12-23 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
| JP7398448B2 (ja) | 2018-10-24 | 2023-12-14 | ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド | ヒト免疫不全ウイルス複製の阻害剤 |
| US20210393633A1 (en) * | 2018-10-25 | 2021-12-23 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
| US20210403465A1 (en) | 2018-10-29 | 2021-12-30 | VIIV Healthcare UK (No.5) Limited | Quinazolinyl-indazole derivatives and their use as inhibitors of human immunodeficiency virus replication |
| US20210395248A1 (en) | 2018-11-05 | 2021-12-23 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
| EP3876942A1 (en) | 2018-11-05 | 2021-09-15 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
| UY38559A (es) | 2019-02-01 | 2020-07-31 | Viiv Healthcare Uk No 5 Ltd | Inhibidores de la replicación del virus de la inmunodeficiencia humana |
| WO2020197991A1 (en) | 2019-03-22 | 2020-10-01 | Gilead Sciences, Inc. | Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use |
| EP3962603A1 (en) | 2019-04-30 | 2022-03-09 | ViiV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
| PE20220510A1 (es) | 2019-06-19 | 2022-04-07 | Viiv Healthcare Uk No 5 Ltd | Inhibidores de la replicacion del virus de inmunodeficiencia humana |
| US20220389007A1 (en) | 2019-10-01 | 2022-12-08 | Viiv Healthcare Uk (No. 5) Limited | Inhibitors of human immunodeficiency virus replication |
| WO2021064570A1 (en) | 2019-10-01 | 2021-04-08 | VIIV Healthcare UK (No.5) Limited | N-substututed-6-oxo-1,6-dihydropyrimidine-2-yl derivatives as inhibitors of the human immunodeficiency virus replication |
| TW202128648A (zh) | 2019-10-04 | 2021-08-01 | 英商Ｖｉｉｖ醫療保健英國(Ｎｏ 5)有限公司 | 人類免疫不全病毒複製之抑制劑 |
| EP4041729B1 (en) | 2019-10-08 | 2023-09-27 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
| US11807625B2 (en) | 2019-11-26 | 2023-11-07 | Gilead Sciences, Inc. | Capsid inhibitors for the prevention of HIV |
| JPWO2021107066A1 (OSRAM) | 2019-11-28 | 2021-06-03 | ||
| MX2022006489A (es) * | 2019-11-29 | 2022-07-04 | Jiangsu Hengrui Medicine Co | Derivado de anillo de piridina fusionado, metodo de preparacion y usos farmaceuticos del mismo. |
| JP2023513047A (ja) * | 2020-01-30 | 2023-03-30 | シンジェンタ クロップ プロテクション アクチェンゲゼルシャフト | 殺有害生物的に有効な縮合二環式芳香族複素環式アミノ化合物 |
| WO2021176367A1 (en) | 2020-03-06 | 2021-09-10 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
| KR20220151655A (ko) * | 2020-03-06 | 2022-11-15 | 비브 헬스케어 유케이 (넘버5) 리미티드 | 인간 면역결핍 바이러스 복제의 억제제 |
| TW202421168A (zh) | 2020-03-20 | 2024-06-01 | 美商基利科學股份有限公司 | 4’-c-經取代-2-鹵基-2’-去氧腺苷核苷之前藥及其製造與使用方法 |
| CN115397424A (zh) | 2020-04-15 | 2022-11-25 | Viiv保健英国第五有限公司 | 人类免疫缺陷病毒复制的抑制剂 |
| TW202502766A (zh) | 2020-06-25 | 2025-01-16 | 美商基利科學股份有限公司 | 用於治療hiv之蛋白殼抑制劑 |
| TWI815194B (zh) | 2020-10-22 | 2023-09-11 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
| WO2022103758A1 (en) | 2020-11-11 | 2022-05-19 | Gilead Sciences, Inc. | METHODS OF IDENTIFYING HIV PATIENTS SENSITIVE TO THERAPY WITH gp120 CD4 BINDING SITE-DIRECTED ANTIBODIES |
| EP4361140A4 (en) * | 2021-05-28 | 2025-09-03 | Jiangsu Hengrui Pharmaceuticals Co Ltd | PHARMACEUTICALLY ACCEPTABLE SALT AND CRYSTALLINE FORM OF FUSED CYCLIC PYRIDINE DERIVATIVE AND PROCESS FOR PREPARATION THEREOF |
| JP7765637B2 (ja) | 2021-12-03 | 2025-11-06 | ギリアード サイエンシーズ， インコーポレイテッド | Ｈｉｖウイルス感染症のための治療化合物 |
| CN118369316A (zh) | 2021-12-03 | 2024-07-19 | 吉利德科学公司 | Hiv病毒感染的治疗性化合物 |
| CA3235937A1 (en) | 2021-12-03 | 2023-06-08 | Gilead Sciences, Inc. | Therapeutic compounds for hiv virus infection |
| TWI843506B (zh) | 2022-04-06 | 2024-05-21 | 美商基利科學股份有限公司 | 橋聯三環胺甲醯基吡啶酮化合物及其用途 |
| TW202434566A (zh) | 2022-07-01 | 2024-09-01 | 美商基利科學股份有限公司 | 可用於hiv病毒感染之疾病預防性或治療性治療的治療性化合物 |
| AU2023330037A1 (en) | 2022-08-26 | 2025-03-06 | Gilead Sciences, Inc. | Dosing and scheduling regimen for broadly neutralizing antibodies |
| EP4598934A1 (en) | 2022-10-04 | 2025-08-13 | Gilead Sciences, Inc. | 4'-thionucleoside analogues and their pharmaceutical use |
| AR132464A1 (es) | 2023-04-19 | 2025-07-02 | Gilead Sciences Inc | Régimen de dosificación de inhibidor de la cápside |
| WO2024249592A1 (en) | 2023-05-31 | 2024-12-05 | Gilead Sciences, Inc. | Quinazolinyl-indazole derivatives as therapeutic compounds for hiv |
| TW202504592A (zh) | 2023-05-31 | 2025-02-01 | 美商基利科學股份有限公司 | 固體形式 |
| AR132951A1 (es) | 2023-06-15 | 2025-08-13 | Viiv Healthcare Uk No 5 Ltd | Métodos e intermedios para preparar compuestos |
| WO2025029247A1 (en) | 2023-07-28 | 2025-02-06 | Gilead Sciences, Inc. | Weekly regimen of lenacapavir for the treatment and prevention of hiv |
| WO2025042394A1 (en) | 2023-08-23 | 2025-02-27 | Gilead Sciences, Inc. | Dosing regimen of hiv capsid inhibitor |
| WO2025080850A1 (en) | 2023-10-11 | 2025-04-17 | Gilead Sciences, Inc. | Bridged tricyclic carbamoylpyridone compounds and uses thereof |
| US20250122219A1 (en) | 2023-10-11 | 2025-04-17 | Gilead Sciences, Inc. | Bridged tricyclic carbamoylpyridone compounds and uses thereof |
| TW202515549A (zh) | 2023-10-11 | 2025-04-16 | 美商基利科學股份有限公司 | 橋聯三環胺甲醯基吡啶酮化合物及其用途 |
| WO2025137245A1 (en) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Solid forms of hiv integrase inhibitors |
| WO2025169059A1 (en) | 2024-02-05 | 2025-08-14 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
| US20250333424A1 (en) | 2024-03-01 | 2025-10-30 | Gilead Sciences, Inc. | Antiviral compounds |
| WO2025184447A1 (en) | 2024-03-01 | 2025-09-04 | Gilead Sciences, Inc. | Pharmaceutical compositions comprising hiv integrase inhibitors |
| US20250289822A1 (en) | 2024-03-01 | 2025-09-18 | Gilead Sciences, Inc. | Solid forms of hiv integrase inhibitors |
| US20250367382A1 (en) | 2024-05-14 | 2025-12-04 | Gilead Sciences, Inc. | Medical injections and related devices and methods |
| WO2025240393A1 (en) | 2024-05-14 | 2025-11-20 | Gilead Sciences, Inc. | Medical injections and related devices and methods |
| WO2025240387A1 (en) | 2024-05-14 | 2025-11-20 | Gilead Sciences, Inc. | Medical injections and related devices and methods |
| US20250367386A1 (en) | 2024-05-14 | 2025-12-04 | Gilead Sciences, Inc. | Medical injections and related devices and methods |
| US20250367385A1 (en) | 2024-05-14 | 2025-12-04 | Gilead Sciences, Inc. | Medical injections and related devices and methods |
| WO2025260028A1 (en) | 2024-06-14 | 2025-12-18 | Gilead Sciences, Inc. | Pharmaceutical compositions comprising hiv integrase inhibitors |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2566481T3 (es) * | 2006-04-12 | 2016-04-13 | Merck Sharp & Dohme Corp. | Antagonistas del canal de calcio de tipo T de piridil amida |
| RU2010120671A (ru) * | 2007-10-24 | 2011-11-27 | Мерк Шарп Энд Домэ Корп. (Us) | Гетероциклические фениламидные антагонисты кальциевых каналов т-типа |
| US20100249176A1 (en) | 2007-10-24 | 2010-09-30 | Barrow James C | Heterocycle amide t-type calcium channel antagonists |
| WO2009062285A1 (en) | 2007-11-16 | 2009-05-22 | Boehringer Ingelheim International Gmbh | Inhibitors of human immunodeficiency virus replication |
| PE20120616A1 (es) | 2009-02-25 | 2012-05-26 | Bigtec Private Ltd | Sondas y cebadores para la deteccion de chikungunya |
| US8338441B2 (en) | 2009-05-15 | 2012-12-25 | Gilead Sciences, Inc. | Inhibitors of human immunodeficiency virus replication |
| US20110035387A1 (en) * | 2009-08-10 | 2011-02-10 | Telcordia Technologies, Inc. | System and method for the controlled introduction of noise to information filtering |
| WO2011094890A1 (en) | 2010-02-02 | 2011-08-11 | Argusina Inc. | Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators |
| US20130165489A1 (en) | 2010-05-03 | 2013-06-27 | The Trustees Of The University Of Pennsylvania | Small Molecule Modulators of HIV-1 Capsid Stability and Methods Thereof |
| WO2011143772A1 (en) | 2010-05-21 | 2011-11-24 | Boehringer Ingelheim International Gmbh | Inhibitors of hiv replication |
| EP2588450B1 (en) | 2010-07-02 | 2017-05-24 | Gilead Sciences, Inc. | Napht-2-ylacetic acid derivatives to treat aids |
| SG186821A1 (en) | 2010-07-02 | 2013-02-28 | Gilead Sciences Inc | 2 -quinolinyl- acetic acid derivatives as hiv antiviral compounds |
| CN102464654B (zh) | 2010-11-12 | 2016-01-13 | 上海泓博智源医药技术有限公司 | 抗病毒化合物 |
| PL2688403T3 (pl) | 2011-03-23 | 2017-09-29 | Trevena, Inc. | Ligandy receptora opioidowego oraz sposoby ich stosowania i wytwarzania |
| SG194512A1 (en) | 2011-04-21 | 2013-12-30 | Gilead Sciences Inc | Benzothiazole compounds and their pharmaceutical use |
| ES2553449T3 (es) | 2011-07-06 | 2015-12-09 | Gilead Sciences, Inc. | Compuestos para el tratamiento de VIH |
| CN102863512B (zh) * | 2011-07-07 | 2016-04-20 | 上海泓博智源医药技术有限公司 | 抗病毒化合物 |
| EP2736332A4 (en) * | 2011-07-29 | 2015-03-18 | Tempero Pharmaceuticals Inc | CONNECTIONS AND METHODS |
| CA2850881C (en) | 2012-04-20 | 2021-02-16 | Gilead Sciences, Inc. | Benzothiazol-6-yl acetic acid derivatives and their use for treating an hiv infection |
| GB201213087D0 (en) | 2012-07-24 | 2012-09-05 | Medical Res Council | Inhibition of HIV-1 infection |
| US9447134B2 (en) | 2012-08-17 | 2016-09-20 | Brandeis University | Compounds and methods for treating mammalian gastrointestinal microbial infections |
| TW201443037A (zh) | 2013-01-09 | 2014-11-16 | Gilead Sciences Inc | 治療用化合物 |
| EP2943487B1 (en) | 2013-01-09 | 2016-11-16 | Gilead Sciences, Inc. | 5-membered heteroaryls and their use as antiviral agents |
| EP2943493B1 (en) | 2013-01-09 | 2017-08-02 | Gilead Sciences, Inc. | Therapeutic compounds for the treatment of viral infections |
| US20140296266A1 (en) | 2013-03-01 | 2014-10-02 | Gilead Sciences, Inc. | Therapeutic compounds |
| TWI694071B (zh) | 2013-03-01 | 2020-05-21 | 美商基利科學股份有限公司 | 治療反轉錄病毒科(Retroviridae)病毒感染之治療性化合物 |
| GB201312991D0 (en) | 2013-07-19 | 2013-09-04 | Isis Innovation | Process |
| JP6466433B2 (ja) | 2013-10-24 | 2019-02-06 | ビーブ・ヘルスケア・ユーケイ・（ナンバー５）・リミテッドＶｉｉＶ Ｈｅａｌｔｈｃａｒｅ ＵＫ （Ｎｏ．５） Ｌｉｍｉｔｅｄ | ヒト免疫不全ウイルス複製の阻害剤 |
| US10202353B2 (en) | 2014-02-28 | 2019-02-12 | Gilead Sciences, Inc. | Therapeutic compounds |
| WO2015130966A1 (en) | 2014-02-28 | 2015-09-03 | Gilead Sciences, Inc. | Antiviral agents |
| EP3186239B1 (en) | 2014-08-29 | 2018-10-10 | Gilead Sciences, Inc. | Antiretroviral agents |
| WO2016040084A1 (en) | 2014-09-09 | 2016-03-17 | Bristol-Myers Squibb Company | Inhibitors of human immunodeficiency virus replication |
| JP2018513183A (ja) | 2015-04-23 | 2018-05-24 | ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド | ヒト免疫不全ウイルス複製の阻害剤 |
| RU2017138972A (ru) | 2015-04-23 | 2019-05-23 | ВАЙВ ХЕЛТКЕР ЮКей (N5) ЛИМИТЕД | Ингибиторы репликации вируса иммунодефицита человека |
| JP6620763B2 (ja) * | 2017-01-16 | 2019-12-18 | マツダ株式会社 | 電動車両 |
-
2014
- 2014-02-27 TW TW103106785A patent/TWI694071B/zh active
- 2014-02-27 TW TW108101371A patent/TWI706945B/zh active
- 2014-02-28 LT LTEP14712844.1T patent/LT2961742T/lt unknown
- 2014-02-28 PL PL18181536T patent/PL3409667T3/pl unknown
- 2014-02-28 AP AP2015008717A patent/AP2015008717A0/xx unknown
- 2014-02-28 WO PCT/US2014/019663 patent/WO2014134566A2/en not_active Ceased
- 2014-02-28 EP EP14712844.1A patent/EP2961742B1/en active Active
- 2014-02-28 BR BR112015021027-9A patent/BR112015021027B1/pt active IP Right Grant
- 2014-02-28 PE PE2015001811A patent/PE20151749A1/es unknown
- 2014-02-28 CN CN201480020587.0A patent/CN105705500B/zh active Active
- 2014-02-28 CN CN201810393664.7A patent/CN108516974A/zh active Pending
- 2014-02-28 JP JP2015560381A patent/JP6519486B2/ja active Active
- 2014-02-28 EP EP18181536.6A patent/EP3409667B1/en active Active
- 2014-02-28 HK HK16114621.0A patent/HK1226078B/zh unknown
- 2014-02-28 ES ES14712844.1T patent/ES2688571T3/es active Active
- 2014-02-28 EP EP21184874.2A patent/EP3954679A3/en active Pending
- 2014-02-28 PL PL14712844T patent/PL2961742T3/pl unknown
- 2014-02-28 HR HRP20181679TT patent/HRP20181679T1/hr unknown
- 2014-02-28 CA CA3007006A patent/CA3007006A1/en not_active Abandoned
- 2014-02-28 MX MX2015011478A patent/MX375170B/es active IP Right Grant
- 2014-02-28 CR CR20190504A patent/CR20190504A/es unknown
- 2014-02-28 SI SI201430847T patent/SI2961742T1/sl unknown
- 2014-02-28 MD MDA20150092A patent/MD20150092A2/ro not_active Application Discontinuation
- 2014-02-28 ES ES18181536T patent/ES2887578T3/es active Active
- 2014-02-28 CA CA2901502A patent/CA2901502C/en active Active
- 2014-02-28 SI SI201431878T patent/SI3409667T1/sl unknown
- 2014-02-28 PT PT14712844T patent/PT2961742T/pt unknown
- 2014-02-28 NZ NZ631754A patent/NZ631754A/en unknown
- 2014-02-28 PE PE2019001438A patent/PE20191461A1/es unknown
- 2014-02-28 PT PT181815366T patent/PT3409667T/pt unknown
- 2014-02-28 HU HUE14712844A patent/HUE039521T2/hu unknown
- 2014-02-28 UA UAA201508564A patent/UA120346C2/uk unknown
- 2014-02-28 SG SG11201506929VA patent/SG11201506929VA/en unknown
- 2014-02-28 NZ NZ728537A patent/NZ728537A/en unknown
- 2014-02-28 US US14/771,779 patent/US9951043B2/en active Active
- 2014-02-28 NZ NZ742681A patent/NZ742681A/en not_active IP Right Cessation
- 2014-02-28 SG SG10201710764YA patent/SG10201710764YA/en unknown
- 2014-02-28 EA EA201591457A patent/EA035127B1/ru unknown
- 2014-02-28 RS RS20181186A patent/RS57718B1/sr unknown
- 2014-02-28 DK DK14712844.1T patent/DK2961742T3/en active
- 2014-02-28 CU CUP2015000096A patent/CU24340B1/xx unknown
- 2014-02-28 MY MYPI2015002119A patent/MY195364A/en unknown
- 2014-02-28 KR KR1020157026837A patent/KR102229989B1/ko active Active
- 2014-02-28 SM SM20180522T patent/SMT201800522T1/it unknown
- 2014-02-28 US US14/194,623 patent/US20140303164A1/en not_active Abandoned
- 2014-02-28 AU AU2014223973A patent/AU2014223973B2/en active Active
- 2014-03-05 UY UY0001035362A patent/UY35362A/es not_active Application Discontinuation
-
2015
- 2015-08-12 IL IL240519A patent/IL240519B/en active IP Right Grant
- 2015-08-21 ZA ZA2015/06098A patent/ZA201506098B/en unknown
- 2015-08-26 PH PH12015501881A patent/PH12015501881B1/en unknown
- 2015-08-31 CL CL2015002445A patent/CL2015002445A1/es unknown
- 2015-09-01 CR CR20150454A patent/CR20150454A/es unknown
-
2016
- 2016-11-22 AU AU2016262671A patent/AU2016262671B2/en active Active
- 2016-12-22 HK HK18114165.0A patent/HK1260892A1/zh unknown
-
2018
- 2018-03-02 US US15/910,083 patent/US20180273508A1/en not_active Abandoned
- 2018-06-15 JP JP2018114786A patent/JP6893899B2/ja active Active
- 2018-09-12 CY CY181100946T patent/CY1121047T1/el unknown
- 2018-10-15 AU AU2018247348A patent/AU2018247348A1/en not_active Abandoned
-
2019
- 2019-08-16 JP JP2019149366A patent/JP2019214599A/ja not_active Withdrawn
-
2020
- 2020-05-26 US US16/882,804 patent/US20210009555A1/en active Pending
-
2021
- 2021-10-29 JP JP2021177617A patent/JP2022009742A/ja not_active Withdrawn
-
2023
- 2023-05-31 JP JP2023090106A patent/JP2023101723A/ja not_active Withdrawn
-
2025
- 2025-03-12 JP JP2025039673A patent/JP2025085700A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016510038A5 (OSRAM) | ||
| CA2972014A1 (en) | Fused pyrimidine compounds for the treatment of hiv | |
| RU2350605C2 (ru) | Аналоги хиназолина в качестве ингибиторов рецепторных тирозинкиназ | |
| JP2016527217A5 (OSRAM) | ||
| JP2015520769A5 (OSRAM) | ||
| JP2016509047A5 (OSRAM) | ||
| JP2019500387A5 (OSRAM) | ||
| JP2019501133A5 (OSRAM) | ||
| JP2017522273A5 (OSRAM) | ||
| JP2015511638A5 (OSRAM) | ||
| JP2016506962A5 (OSRAM) | ||
| JP2009538897A5 (OSRAM) | ||
| JP2016506959A5 (OSRAM) | ||
| AR072249A1 (es) | Inhibidores de amida hidrolasa de acido graso. usos. metodos. | |
| JP2014511892A5 (OSRAM) | ||
| JP2011529474A (ja) | ｃｄｋ阻害剤および抗悪性腫瘍剤を含む治療用組合せ | |
| JP2016506961A5 (OSRAM) | ||
| JP2017526677A5 (OSRAM) | ||
| JP2020507589A5 (OSRAM) | ||
| JP2011521938A5 (OSRAM) | ||
| JP2018527301A5 (ja) | アジリジン含有ｄｎａアルキル化剤 | |
| JP2017525699A5 (OSRAM) | ||
| JP2008517923A5 (OSRAM) | ||
| RU2016142611A (ru) | Пролекарственные средства ингибиторов обратной транскриптазы вич | |
| JP2016512507A5 (OSRAM) |